Financial incentives for generic drugs: case study on a reimbursement program

被引:0
|
作者
Inocencio, Marcos [1 ]
Sanches Amorim, Maria Cristina [2 ,3 ]
de Hoyos Guevara, Arnoldo Jose [3 ]
de Vivo, Bruna [4 ]
机构
[1] Pontificia Univ Catolica Sao Paulo PUC SP, Business Adm, Sao Paulo, SP, Brazil
[2] Pontificia Univ Catolica Sao Paulo PUC SP, Dept Econ, Sao Paulo, SP, Brazil
[3] Pontificia Univ Catolica Sao Paulo PUC SP, Grad Program Business Adm, Sao Paulo, SP, Brazil
[4] Pontificia Univ Catolica Sao Paulo PUC SP, Hlth Econ & Management, Sao Paulo, SP, Brazil
来源
EINSTEIN-SAO PAULO | 2010年 / 8卷 / 02期
关键词
Reference drugs; Health management; Drugs; generic/supply & distribution; Reimbursement; incentive/economics;
D O I
10.1590/s1679-45082010ao1478
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To discuss the use of financial incentives in choice of medication and to assess the economic results concerning the use of financial incentives to promote the use of genetic medication in lieu of reference drugs in a company with a reimbursement program. Methods: A case study was carried out in a large supermarket. The data was obtained in the company responsible for managing medication. The study reached 83,625 users between August 2005 and July 2007. The data was submitted to regressions in order to analyze trends and hypothesis tests to assess differences in medication consumption. The results were compared with general data regarding medication consumption of five other organizations and also with data about the national consumption of generic medication in Brazil. Results: The use of financial incentives to replace brand medications for generics, in the company studied, increased the consumption of generic drugs without reducing the company expenses with the reimbursement programs. Conclusions: This study show the occurrence of unplanned results (increase in the consumption of medications) and the positive consequences of the reimbursement program concerning access to medication.
引用
收藏
页码:154 / 161
页数:8
相关论文
共 50 条
  • [21] Effective intervention to reduce occupational injuries in Alberta: A case study of financial incentives
    Guidotti, TL
    OCCUPATIONAL MEDICINE-STATE OF THE ART REVIEWS, 1998, 13 (02): : 443 - 449
  • [22] Barriers and facilitators to enrolling in a cancer clinical trial financial reimbursement program
    Nguyen, Vivian
    Ramos, Elizabeth
    Dornsife, Dana
    Johnson, Robert G.
    Miller, Erin
    Jones, Mallorie
    Uribe, Daniela
    Wileyto, E. Paul
    Vonderheide, Robert H.
    Guerra, Carmen
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] The effect of financial incentives on smoking cessation program attendance and completion
    Volpp, KG
    Gurmankin, A
    Asch, DA
    Murphy, J
    Sox, H
    Gomez, A
    Lerman, C
    CIRCULATION, 2004, 109 (20) : E256 - E256
  • [24] Third-party reimbursement for generic prescription drugs: The prevalence of below-cost reimbursement in an environment of maximum allowable cost-based reimbursement
    Murry, Logan
    Gerleman, Brandon
    Urick, Benjamin
    Urmie, Julie
    JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2018, 58 (04) : 421 - 425
  • [25] On reimbursement reforms and stockpiling of prescription drugs: The case of insulin
    Skipper, Niels
    HEALTH POLICY, 2012, 106 (03) : 233 - 240
  • [26] Cardiovascular drugs: prescription profiles and the economic impact of a generic-based reimbursement system
    Cinemre-Solmaz, Nuha B.
    Burat, Kutlay
    Rabus, Sule Apikoglu
    PHARMACY WORLD & SCIENCE, 2008, 30 (05): : 716 - 717
  • [27] Pricing and reimbursement of generic pharmaceuticals in Turkey: Evaluation of hypertension drugs from 2007 to 2013
    Kumru, Seda
    Top, Mehmet
    HEALTH POLICY AND TECHNOLOGY, 2018, 7 (02) : 182 - 193
  • [28] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
    Rinke van den Brink
    Orphanet Journal of Rare Diseases, 9 (Suppl 1)
  • [29] Generic Drugs and Innovative Drug Incentives: Early Dispute Resolution Mechanism in China
    Jiang, Li
    Yang, Hong
    BIOTECHNOLOGY LAW REPORT, 2022, 41 (04) : 186 - 193
  • [30] Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries
    Post, H. C.
    Schutte, T.
    van Oijen, M. G. H.
    van Laarhoven, H. W. M.
    Hollak, C. E. M.
    ESMO OPEN, 2023, 8 (02)